IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole (Q44134557)

30 November 2017

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole (English)

1 reference

30 November 2017

Jack Cuzick

1

1 reference

30 November 2017

1 September 2008

1 reference

Expert Review of Anticancer Therapy

30 November 2017

1 reference

30 November 2017

8

1 reference

30 November 2017

9

1 reference

30 November 2017

1377-1385

1 reference

The decrease in breast-cancer incidence in 2003 in the United States

30 November 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Lifetime recreational exercise activity and breast cancer risk among black women and white women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Recreational physical activity and risk of postmenopausal breast cancer in a large cohort of US women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Physical activity and risk of breast cancer in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Breast cancer among former college athletes compared to non-athletes: a 15-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Aromatase inhibitors for breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Multiple primary cancers involving the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Risk of contralateral breast cancer among women with carcinoma in situ of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Tolerance of adjuvant letrozole outside of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

Breast cancer and hormone-replacement therapy: the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1377

10.1586/14737140.8.9.1377

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

18759690